Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6093 in advanced KRAS G12D mutant solid tumors
NCT07134998Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-6093 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Adverse Events/Serious Adverse Events, Dose-Limiting Toxicity and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
HRS-6093
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07134998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134998.